Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer.

Therapies 130

Therapies Immune Response Licensing Licensing 130

Drug Target Review

JULY 4, 2023

In the realm of immunology, researchers are constantly striving to unlock the intricate secrets of the human immune system. Among the many remarkable components that make up this complex defence network, T cells have emerged as powerful guardians, orchestrating an array of immune responses with great precision.

Immune Response 52

Immune Response Engineering Treatment Therapies 52

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

SEPTEMBER 28, 2023

The company demonstrated that resminostat is well tolerated and can inhibit tumour growth and proliferation, cause tumour regression, and strengthen the body’s immune response to cancer in the RESMAIN study. Currently, CTCL is incurable and treatment options for advanced-stage CTCL are limited.

Therapies 130

Therapies Immune Response FDA Treatment 130

Drug Discovery World

AUGUST 7, 2023

The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease. Susmita Sahoo, Associate Professor of Medicine, Cardiology at Icahn Mount Sinai has been exploring the use of exosomes in gene therapy for several years.

Therapies 130

Therapies Disease Research Immune Response 130

Drug Discovery World

OCTOBER 25, 2023

Gamida Cell has revealed early data in 10 patients with CD20 positive non-Hodgkin lymphoma as part of an ongoing study of natural killer (NK) cell therapy candidate GDA-201. The post Natural killer cell therapy shows powerful anti-tumour activity appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Immune Response Science Treatment 130

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.”

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Discovery World

FEBRUARY 19, 2024

C-peptide levels reached normal levels and there was no indication that the allogeneic HIP p-islet graft induced any immune recognition or any type of immune response at any time. The development of cell therapies that replace the loss of insulin-producing cells could one day offer cures for type 1 diabetes.

Therapies 130

Therapies Immune Response Engineering Trials 130

Chemical Biology and Drug Design

FEBRUARY 2, 2024

Terpenes are compounds that inhibit the growth of Leishmania spp, Schistosoma spp, and Echinococcus spp, cause changes in parasite ultrastructure, inhibit enzyme activity, and modulate the immune response. Their use in combination therapy decreases the concentration of the reference drug used.

Treatment 100

Treatment Disease Immune Response Therapies 100

Drug Target Review

JUNE 27, 2023

This ebook delves into the intricate world of cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and groundbreaking advancements in gene editing, featuring insightful interviews with renowned experts in the field.

Therapies 105

Therapies Immune Response Engineering Drugs 105

Drug Target Review

JANUARY 15, 2024

Research 1 has shown that neutrophil elastase selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilises adaptive immunity, and avoids resistance mechanisms. Could you provide insights into the driving factors behind exploring novel treatments for cancer types?

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Drug Discovery World

JANUARY 12, 2024

Researchers in the US have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer. In the future, these cells could be manufactured, preserved by freezing, and then administered to patients.

Research 291

Research Immune Response Virus Therapies 291

Drug Discovery World

AUGUST 7, 2024

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development.

Drug Trials 148

Drug Trials FDA Trials Immune Response 148

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. Advances in understanding treatment resistant cancer cells (part 1).

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Science Daily: Pharmacology News

OCTOBER 18, 2023

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months.

Therapies 77

Therapies Immune Response Research Virus 77

Drug Discovery World

FEBRUARY 24, 2023

For this evaluation, participants underwent an analytical treatment interruption (ATI) in their antiretroviral therapy (ART) for up to 24 weeks. The data show that a higher proportion of HTI+VES-treated participants remained off ART for the full 24 weeks.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Olympian Clinical Research

MAY 6, 2024

The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

PLOS: DNA Science

OCTOBER 12, 2023

In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Discovery World

MARCH 19, 2024

AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprogrammes tumour cells into antigen-presenting dendritic cells, ultimately leading to a personalised anti-tumour immune response. We believe this breakthrough strategy will give rise to the next generation of cell therapies.

Immune Response 130

Immune Response Packaging Therapies FDA 130

Drug Discovery World

APRIL 12, 2024

The top stories: Genetically engineered dendritic cells enhance lung cancer therapy A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

Immune Response 130

Immune Response Engineering Drugs Therapies 130

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Discovery World

JULY 12, 2023

Scientists investigating potential drugs to improve recovery from spinal cord injury have uncovered a promising route to new treatments. However, drugs that reduce inflammation by suppressing the whole immune response also inhibit the immune cells which promote repair.

Immune Response 130

Immune Response Drugs Regulations Treatment 130

Olympian Clinical Research

NOVEMBER 30, 2023

While the journey to understand and treat this condition has been complex, recent innovations in vitiligo treatment have opened new doors, offering hope and improved outcomes for those affected. The Evolution of Vitiligo Treatments From ancient remedies to modern medicine, the treatment of vitiligo has undergone a remarkable transformation.

Treatment 52

Treatment Clinical Research Clinical Trials Immune Response 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Drug Discovery World

MAY 23, 2024

The three-year survival rate for children with high-grade gliomas, without further complications, is only 11-22%, and the currently available treatments, radiotherapy and chemotherapy, can harm the child’s developing brain. The virus also increased the number of immunity-boosting white blood cells within the tumours.

Virus 148

Virus Immune Response Vaccine Engineering 148

Drug Discovery World

JULY 5, 2023

Through such therapies, slowly, hesitatingly, some people are using the word ‘cure’ with a few individual cancer patients, which is something the field has avoided for decades. These types of therapies are often more effective and have fewer side effects. These types of therapies are often more effective and have fewer side effects.

Research 246

Research Immune Response Pharmaceutical Companies Treatment 246

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Discovery World

DECEMBER 16, 2022

The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . STC-15 triggers both direct cytotoxic and immune response-based efficacy mechanisms in solid tumour and leukaemia models.

RNA 130

RNA Immune Response Small Molecule Therapies 130

Drug Discovery World

AUGUST 2, 2022

Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova. . NeuroNova is an allogeneic “off-the-shelf” therapy comprised of an immortalised Neural Stem Cell (NSC) line loaded with an engineered oncolytic adenovirus. Camaisa. .

Trials 130

Trials FDA Immune Response Clinical Trials 130

Broad Institute

MARCH 20, 2024

doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). Networks of cells are critical in mediating immune responses. How do immune cells organize within tumors to effectively eliminate cancer cells? Nature Immunology.

Immune Response 131

Immune Response Hospitals Research Treatment 131

Drug Discovery World

APRIL 26, 2024

In addition to encoding the target antigens, mRNA vaccines also provide adjuvant properties that amplify the immune response. This is a really finely honed tool”. “This is very much an individualised therapy and it’s far cleverer in some senses than a vaccine,” said Shaw. “It in the combination arm and 62.2%

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Clinical Trials 130

Clinical Trials Immune Response Trials Drugs 130

Drug Discovery World

AUGUST 16, 2023

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

Immune Response 130

Immune Response Disease Therapies Treatment 130

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. Looking forward Triebel says that present I-O therapies is just the beginning of the story.

Immune Response 246

Immune Response Therapies Vaccine Production 246

Drug Discovery World

APRIL 16, 2023

Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130